Skip to content

Released Oct 7, 2026, after the close

10-Q filed Nov 5, 2026, 36 days after period end · 0001104659-26-123458

Q3 2026 · 10-Q
Revenue$9.83M+94.3% vs Q3 2025+295.9% vs Q2 2026
Net Income-$7.72MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.21N/M vs Q3 2025N/M vs Q2 2026
Gross Profit$7,680,000+95.4%
Operating Income-$7,821,000N/M
Operating Cash Flowderived-$5,006,000N/M
Margins · derived
Gross margin78.1%+0.4 pt vs Q3 2025
Operating margin-79.6%+96.6 pt vs Q3 2025
Net margin-78.6%+79.1 pt vs Q3 2025

What the release said

Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall Street expectations.

Profound expects preliminary unaudited third-quarter 2026 revenue of $9.8 million to $10.0 million and gross margin to exceed 70%.23

Revenue is expected to increase 85% to 89% year over year from $5.3 million in the third quarter of 2025, and 292% to 300% sequentially from $2.5 million in the second quarter of 2026.45

Expected revenue is 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, and Profound plans to report full third-quarter results after market close on November 5, 2026.36

Expected total revenue
$9.8 million to $10.0 million2
Expected year-over-year revenue growth
85% to 89% Compared with the third quarter of 20254
Prior-year revenue
$5.3 million Third quarter of 20254
Expected gross margin
70% Q3-2026, expected to exceed this level3
Bloomberg mean analyst consensus
$6.78 million Revenue consensus3
Revenue above consensus
45% to 47% Compared with the Bloomberg mean analyst consensus3
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024
Revenue$9.83M$5.06M$2.54M
Net Income-$7.72M-$7.98M-$9.37M
EPS Diluted-$0.21-$0.26$0.38

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR